Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof

Patent metadata

Field	Value
Publication number	US-9757358-B2
Application number	US-201113574121-A
Country	US
Kind code	B2
Filing date	Feb 4, 2011
Priority date	Feb 4, 2010
Publication date	Sep 12, 2017
Grant date	Sep 12, 2017

Abstract

The invention refers to a combination comprising a sigma ligand of formula (I) and an opioid or opiate for use in the prevention and/or treatment of pain developed as a consequence of surgery, especially peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis or neuropathy. The invention also refers to the sigma ligands of formula (I) for use in potentiating the analgesic effect of an opioid or opiate and/or for decreasing the dependency induced thereby when said opioid or opiate is used in the prevention and/or treatment of pain developed as a consequence of surgery.

First claim

The invention claimed is:

1. A method of treatment of a patient suffering from pain developed as a consequence of surgery, or a patient likely to suffer pain as a result of a surgical treatment, which comprises administering to the patient an amount of:
i) an opioid or opiate selected from the group consisting of morphine, tramadol, sufentanil, remifentanil, fentanyl, tapentadol, oxycodone, and buprenorphine, and
ii) 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine or a pharmaceutically acceptable salt, isomer or solvate thereof, which amounts in combination are effective to treat the pain of the patient.

2. The method according to claim 1 comprising administering a therapeutically effective amount of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride.

3. The method according to claim 1 comprising administering a therapeutically effective amount of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride and an opioid or opiate selected from the group consisting of morphine, tramadol, sufentanil, remifentanil, fentanyl, tapentadol, oxycodone, and buprenorphine.

4. A method for potentiating the analgesic effect of an opioid or opiate in a patient while also decreasing the dependency of the patient induced thereby when said opioid or opiate is administered in the prevention or treatment of pain that is a consequence of surgery, wherein said opioid or opiate is selected from the group consisting of morphine, tramadol, sufentanil, remifentanil, fentanyl, tapentadol, oxycodone, and buprenorphine, which comprises administering to the patient a therapeutically effective amount of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine or a pharmaceutically acceptable salt, isomer or solvate thereof.

5. The method according to claim 4 comprising administering a therapeutically effective amount of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride.

6. The method according to claim 1 comprising administering a therapeutically effective amount of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride and morphine.

7. The method according to claim 1 comprising administering a therapeutically effective amount of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride and tramadol.

8. The method according to claim 1 comprising administering a therapeutically effective amount of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride and sufentanil.

9. The method according to claim 1 comprising administering a therapeutically effective amount of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride and remifentanil.

10. The method according to claim 1 comprising administering a therapeutically effective amount of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride and fentanyl.

11. The method according to claim 1 comprising administering a therapeutically effective amount of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride and tapentadol.

12. The method according to claim 1 comprising administering a therapeutically effective amount of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride and oxycodone.

13. The method according to claim 1 comprising administering a therapeutically effective amount of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride and buprenorphine.

14. The method according to claim 1 , wherein opiate or opioid and the 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine or a pharmaceutically acceptable salt, isomer or solvate thereof are administered simultaneously.

15. The method according to claim 1 , wherein opiate or opioid and the 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine or a pharmaceutically acceptable salt, isomer or solvate thereof are administered sequentially.

16. The method according to claim 1 , wherein opiate or opioid and the 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine or a pharmaceutically acceptable salt, isomer or solvate thereof are administered separately.

17. The method according to claim 1 , wherein the 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine or a pharmaceutically acceptable salt, isomer or solvate thereof is administered at a dose of 2.5-80 mg/kg.

18. The method according to claim 1 , wherein the 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine or a pharmaceutically acceptable salt, isomer or solvate thereof is administered at a dose of 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, 40 mg/kg or 80 mg/kg.

Assignees

• Vela Hernández José Miguel
• Zamanillo-Castanedo Daniel
• Esteve Labor Dr

Inventors

• Vela Hernández José Miguel
• Zamanillo-Castanedo Daniel

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K31/4152 Primary

  having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone · CPC title

• A61K31/485

  Morphinan derivatives, e.g. morphine, codeine · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title